Medical device manufacturer NinePoint Medical Inc. has received FDA 510 (k) clearance for its volumetric optical coherence tomography (OCT) imaging system.
Medical device manufacturer NinePoint Medical Inc. has received FDA 510 (k) clearance for its volumetric optical coherence tomography (OCT) imaging system.
NinePoint’s Nvision VLE Imaging System is a tool for the evaluation of human tissue microstructure by providing 2-D, cross-sectional, real-time depth visualization, according to the company. It is the first volumetric OCT device cleared by the FDA for endoscopic imaging that uses a circumferential scanning technique and an automated pullback to generate cross-sectional and longitudinal images simultaneously in real-time, the company said.
The system can image under the mucosal surface at less than 10 micros resolution up to a tissue depth of 3mm, and can image circumferentially or helically up to 6cm in length in less than 100 seconds, the company said.
“The Nvision VLE Imaging System can provide high-resolution images of potentially diseased tissue, which are deeper than can be imaged with endoscopy alone,” Charles Carignan, MD, president and CEO of NinePoint Medical, said in a statement.
“Our initial focus is on providing physicians with higher-resolution cross sectional and longitudinal images of diseased tissue in the epithelium of various organs, which impacts millions of adults in the United States.”
Carignan said the company will be conducting clinical trials of the Nvision VLE Imaging System in 2012 with plans of a commercial launch in 2013.
Study with CT Data Suggests Women with PE Have More Than Triple the One-Year Mortality Rate than Men
April 3rd 2025After a multivariable assessment including age and comorbidities, women with pulmonary embolism (PE) had a 48 percent higher risk of one-year mortality than men with PE, according to a new study involving over 33,000 patients.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Predicting Diabetes on CT Scans: What New Research Reveals with Pancreatic Imaging Biomarkers
March 25th 2025Attenuation-based biomarkers on computed tomography (CT) scans demonstrated a 93 percent interclass correlation coefficient (ICC) agreement across three pancreatic segmentation algorithms for predicting diabetes, according to a study involving over 9,700 patients.
Can Photon-Counting CT be an Alternative to MRI for Assessing Liver Fat Fraction?
March 21st 2025Photon-counting CT fat fraction evaluation offered a maximum sensitivity of 81 percent for detecting steatosis and had a 91 percent ICC agreement with MRI proton density fat fraction assessment, according to new prospective research.